CDC Expands COVID Vaccine Recommendation to All Adults and Many Children After Judge Blocks Narrower Rules

Two vaccine stories are moving in opposite directions this week. One shows the childhood immunization schedule working exactly as designed. The other shows federal vaccine policy getting rewritten by a courtroom, not a lab.

CDC widens the COVID shot recommendation

The CDC now recommends a COVID-19 vaccine for all adults regardless of health status, and for most children ages 6 months to 17 who haven't yet had a dose, according to the Epoch Times. Kids who are moderately or severely immunocompromised are included in that recommendation outright. For previously vaccinated children without weakened immune systems, the CDC says parents should just talk it over with a doctor first.

The FDA only approved the shots for adults 65 and older, plus anyone 6 months and up with a condition like asthma or obesity that raises COVID risk. This means the new CDC recommendation for healthy adults under 65 and for most kids is, in the Epoch Times' words, "partially off-label" — recommended by the agency but outside what the FDA formally signed off on.

This expansion came after a federal judge blocked the administration's previous, narrower recommendation, according to the Epoch Times. The broader guidance wasn't the product of new clinical data pushing officials to widen the recommendation. It was a court order. An appeal of that ruling is ongoing, per the Epoch Times, so this isn't settled policy yet.

Uptake so far has been low. Just 9.7% of children got a COVID vaccine in late 2025 or early 2026, according to CDC estimates cited by the Epoch Times. Most families with kids already aren't choosing the shot.

Critics are not staying quiet. Dr. Mary Talley Bowden, founder of Americans for Health Freedom, told the Epoch Times the move "demonstrates total disregard for safety, the will of the people and administrative transparency." Her camp's core objection isn't that the vaccine doesn't work. It's that a court forced a recommendation broader than what FDA's own approval covers, for a population where the risk-benefit case is genuinely different for a healthy teenager than for a 70-year-old with heart disease.

No source in this reporting disputes that COVID still hospitalizes and kills some people in every age group, and the CDC's position remains that vaccination reduces that risk. But the specific legal and procedural question—whether an off-label CDC recommendation forced by a judge carries the same standing as an FDA-approved indication—is unresolved. A spokesperson for the pediatric academy referenced in the reporting declined to comment when asked, per the Epoch Times.

A Finnish study says the booster shot fixes the gap

While that fight plays out, a separate piece of vaccine science landed in the Journal of Infectious Diseases. Researchers led by Lauri Ivaska, MD, PhD, of the University of Turku in Finland, followed children through age 4 as part of an extension of the Finnish MIFI trial.

All the kids got their standard DTaP shots at 3, 5, and 12 months. But children whose mothers got the Tdap vaccine during pregnancy showed a weaker antibody response to their own pertussis vaccination. By age 3, kids of vaccinated mothers had anti-pertussis toxin IgG levels of 2.44 IU/mL, compared with 5.76 IU/mL in kids of unvaccinated mothers, a statistically significant gap (P=0.002) that held up at age 4, according to MedPage Today and Archyde, both of which independently summarized the same published study.

The blunting is a known tradeoff. Maternal antibodies cross the placenta and protect newborns in the highest-risk window before their own immune system can catch up, but those same antibodies can dampen the infant's reaction to the primary vaccine series. Ivaska's team found children of vaccinated mothers had far higher protective antibody levels at birth, 93.7 IU/mL versus 18.4 IU/mL for anti-PT IgG, and 100% versus 62% diphtheria seroprotection.

After the routine DTaP booster at age 4, the gap closed entirely. Kids of vaccinated mothers hit 247 IU/mL, essentially matching the 270 IU/mL in kids of unvaccinated mothers, MedPage Today reported.

"Maternal Tdap vaccination is a safe and effective strategy for protecting young infants from pertussis, which remains the principal rationale for its use during pregnancy," Ivaska and colleagues wrote, adding that the booster response "appears preserved" despite the temporary blunting.

Lori Handy, MD, associate director of the Vaccine Education Center at Children's Hospital of Philadelphia, told MedPage Today the data reinforce that infants of vaccinated mothers carry strong antibody titers right when they're most vulnerable, in the first three months of life. Infants under 3 months face the highest risk from pertussis; roughly 1 in 100 infected infants dies, per the CDC figures cited by MedPage Today.

The pertussis findings track a settled, incrementally-updated body of evidence. The COVID recommendation doesn't have that luxury. It's a live legal dispute, with an appeal pending and an FDA approval gap that the CDC's own guidance now sits outside of. Parents weighing either vaccine for a child this fall are being asked to navigate two very different kinds of uncertainty: one backed by years of peer-reviewed trial data, the other decided in a courtroom this week.